Vertex Pharma concludes Phase 2 epilepsy trial
The study recruited and dosed people who did not benefit from the use of at least two currently available medicines for partial epilepsy. In the study, the patients
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.